Pravin Dugel's guest appearances

Pravin Dugel

OIS Podcast

The Retina Channel Podcast

Retina Synthesis

Mark Humayun

Jay Cormier

Brent Saunders

David Brown

Daniel Chao

David Muller

Andrew Chang

David Tanzer

Ken Mills

Bill Link

Patrick Mooney

Diana Driscoll

Brent Jones

Jason Hsu

Ponders IPO

OwlTail

Multiple reports have shown that only about 11% of Phase I clinical trials make it through to regulatory approval. Business, says retina expert Pravin Dugel, MD, president of Iveric Bio, follows a similar trajectory. Success comes only after multiple failures. Dr. Dugel has enjoyed success as a retina surgeon, as a principal investigator, and as president of a biopharmaceutical company focused on developing therapies for retinal disease. He became a leader in his field partly due to his fearless risk-taking and his ability to learn from the times when those risks didn’t pan out. An immigrant refugee from Nepal who fled to Austria with his family, Dr. Dugel followed his brother to a boarding school in England, finished high school and college in New York, and moved to the opposite coast to complete medical school, a residency, and a fellowship in southern California.Taking a calculated risk based on what seemed like a promising market, Dr. Dugel moved to Phoenix, Arizona, to build his clinical practice, Retina Consultants of Arizona. Though it took years of trial and error, he succeeded in founding one of the most innovative retina practices in the country. He has also served as principal investigator in more than 100 clinical trials, including known products such as NeoVista and Beovu.With host Firas Rahhal, MD, Dr. Dugel talks about what he and other investigators learned from the NeoVista clinical trials that would inform future protocols. He also discusses the science behind Zimura (avacincaptad pegol), Iveric Bio’s therapy for geographic atrophy, a part of late-stage age-related macular degeneration (AMD). Zimura received a special protocol assessment (SPA) from the Food and Drug Administration, which may help expedite approvals. Trial results from Zimura’s GATHER2 studies are expected in the second half of 2022.Listen to the Podcast to find out:The MOA behind Zimura  and why it may have an impact on intermediate macular degeneration and wet AMD. How Dr. Dugel expanded his career from traditional academic practice to research physician to biopharma entrepreneur, and the one quality that helped him along the way.What went wrong with NeoVista and Beovu and what the industry can learn from these studies.Click “play” to listen.

Multiple reports have shown that only about 11% of Phase I clinical trials make it through to regulatory approval. Business, says retina expert <a href="https://www.linkedin.com/in/pravin-dugel-01060119/" rel="nofollow" target="_blank">Pravin Dugel, MD</a>, president of <a href="https://ivericbio.com/" rel="nofollow" target="_blank">Iveric Bio</a>, follows a similar trajectory. Success comes only after multiple failures. Dr. Dugel has enjoyed success as a retina surgeon, as a principal investigator, and as president of a biopharmaceutical company focused on developing therapies for retinal disease. He became a leader in his field partly due to his fearless risk-taking and his ability to learn from the times when those risks didn’t pan out. An immigrant refugee from Nepal who fled to Austria with his family, Dr. Dugel followed his brother to a boarding school in England, finished high school and college in New York, and moved to the opposite coast to complete medical school, a residency, and a fellowship in southern California.Taking a calculated risk based on what seemed like a promising market, Dr. Dugel moved to Phoenix, Arizona, to build his clinical practice, <a href="https://www.retinalconsultantsaz.com/" rel="nofollow" target="_blank">Retina Consultants of Arizona</a>. Though it took years of trial and error, he succeeded in founding one of the most innovative retina practices in the country. He has also served as principal investigator in more than 100 clinical trials, including known products such as NeoVista and Beovu.With host <a href="https://laretina.com/our-physicians/firas-rahhal-m-d/" rel="nofollow" target="_blank">Firas Rahhal, MD</a>, Dr. Dugel talks about what he and other investigators learned from the NeoVista clinical trials that would inform future protocols. He also discusses the science behind Zimura (avacincaptad pegol), Iveric Bio’s therapy for geographic atrophy, a part of late-stage age-related macular degeneration (AMD). Zimura received a <a href="https://investors.ivericbio.com/news-releases/news-release-details/iveric-bio-receives-fda-agreement-under-special-protocol" rel="nofollow" target="_blank">special protocol assessment (SPA)</a> from the Food and Drug Administration, which may help expedite approvals. Trial results from Zimura’s GATHER2 studies are expected in the second half of 2022. Listen to the Podcast to find out:<ul><li>The MOA behind Zimura  and why it may have an impact on intermediate macular degeneration and wet AMD. </li><li>How Dr. Dugel expanded his career from traditional academic practice to research physician to biopharma entrepreneur, and the one quality that helped him along the way.</li><li>What went wrong with NeoVista and Beovu and what the industry can learn from these studies.</li></ul> Click “play” to listen.

Success From Failure With Iveric Bio’s Dr. Pravin Dugel

Dr. Dugel discusses 1 and 2 year results of HAWK and HARRIER on Brolucizumab for neovascular AMD.  Full reference:  Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., . . . Investigators, H. S. (2019). HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. doi:10.1016/j.ophtha.2019.04.017

Dr. Dugel discusses 1 and 2 year results of HAWK and HARRIER on Brolucizumab for neovascular AMD.  Full reference:  Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., . . . Investigators, H. S. (2019). HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. doi:10.1016/j.ophtha.2019.04.017

E28-Brolucizumab for wet AMD (HAWK and HARRIER)- Dr. Pravin Dugel

Pravin Dugel, MD, managing partner, Retinal Consultants of Arizona, delivers a frank overview of the pipeline of experimental retinal drugs. The next year could be critical for retinal disease as combination therapies and other products push through late-stage clinical trials. What technologies show the most promise? What advances have surprised even him?

Dr. Pravin Dugel Picks Possible Winners in Race to Deliver New Retinal Treatments